Clinical Trials Browser

Phase 1/2 × lorukafusp alfa × 30 days × Clear all

NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Terminated

8 enrolled 12 charts

Melanoma